Carbon 14 and Carbon 13 Syntheses of Velagliflozin.
J Labelled Comp Radiopharm
; 67(5): 180-185, 2024 May 15.
Article
em En
| MEDLINE
| ID: mdl-38605481
ABSTRACT
Velagliflozin is the active ingredient of the first oral liquid medication approved by the Food and Drug Administration for the treatment of diabetes in cats. This compound belongs to the known class of sodium-glucose cotransporter 2 inhibitors approved to treat diabetes in human. Here, we report the detailed synthesis of velagliflozin labeled with carbon 14 and carbon 13.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Isótopos de Carbono
/
Radioisótopos de Carbono
Idioma:
En
Revista:
J Labelled Comp Radiopharm
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Estados Unidos